Analysis of Complications in Patients Receiving Adjuvant Irradiation for Endometrial Carcinoma

Greven, K.M.; Lanciano, Rachelle; Herbert, Saskia-L; Hogan, Patricia E.

doi:10.1016/0360-3016(90)90732-y

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These gains may outcome has yet to be demonstrated since no highly effective therapies have been identified once disease presence outside be decreased further by treatment-related toxicity, which can be substantial in this older population [15][16][17].…”

Section: Methodsmentioning

confidence: 99%

Endometrial Carcinoma—Relative Effectiveness of Adjuvant Irradiation vs Therapy Reserved for Relapse

Ackerman

Malone

Thomas

et al. 1996

Gynecologic Oncology

125

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Endometrial Carcinoma—Relative Effectiveness of Adjuvant Irradiation vs Therapy Reserved for Relapse

Ackerman

Malone

Thomas

et al. 1996

Gynecologic Oncology

125

View full text Add to dashboard Cite

“…Considering the high rate of surgical upstaging seen in previous studies and the metastatic spread pattern, it is possible that the poor survival rates seen in the group of observed patients and in the APRT alone group are at least partially attributed to undetected metastatic disease. We advocate the importance of staging and assessment of occult metastases acknowledging the increased risk of complications, with APRT after transperitoneal para-aortic node dissection (30,31) . However, newer intensity-modulated radiation therapy techniques may overcome this limitation of radiation complications after surgical staging.…”

Section: Discussionmentioning

confidence: 99%

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy

Steed

Manchul

Rosen

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

The aim of this study was to compare overall survival (OS), progression-free survival (PFS), and relapse patterns between different modalities of treatment for uterine papillary serous carcinoma (UPSC). A retrospective review of 124 patients with pathologically confirmed UPSC was performed, of whom, 97 patients were eligible for study. Postoperative treatment groups included adjuvant radiotherapy consisting of whole abdomen and a pelvic boost (abdominopelvic radiotherapy [APRT]) (55 patients), paclitaxel and carboplatin chemotherapy (CT) for six cycles followed by APRT (18 patients), CT only (5 patients), and 19 patients were observed without postoperative adjuvant therapy. Three-year OS was 81% and 63% for the CT followed by APRT and APRT alone, respectively (P= 0.11). After controlling for stage, the group treated with APRT alone had significantly decreased OS and PFS compared to the CT/APRT group (HR 3.6; 1.3–9.8; P= 0.01) and (HR 2.9; 95% CI 1.1–7.3; P= 0.03), respectively. Within the limitations of a retrospective study, the results of this study indicate that multimodality postoperative treatment with paclitaxel and a platinum-based CT followed by APRT may increase the survival of patients with UPSC. However, further prospective studies using these combined modalities are needed to confirm these findings.

show abstract

“…Although one patient with diverticulosis developed a colovaginal fistula the role of brachytherapy is uncertain and the authors have encountered these in other nonirradiated patients. In a retrospective review of radiation toxicity, Grade 2 proctitis with moderate diarrhea and intermittent bleeding occurred in only 1 of 75 patients after brachytherapy alone ( 19 ) . In contrast, whole pelvic radiation therapy is significantly more morbid with a 4% serious (requiring reoperation) complication rate ( 19 ) .…”

Section: Discussionmentioning

confidence: 99%

Brachytherapy for early endometrial carcinoma: a comparative study with long-term follow-up

Rose¹,

Tak²,

Fitzgerald³

et al. 1999

Int J Gynecol Cancer

View full text Add to dashboard Cite

The current study was undertaken to evaluate the effect of preoperative uterine or postoperative vaginal brachytherapy compared to no adjuvant therapy on the disease-free interval, sites of recurrence, and survival in favorable stage IB endometrial carcinoma. One hundred and forty-six patients with FIGO grade 1 and 2 endometrial carcinoma and 1-33% myometrial invasion treated between 1974 and 1992 were retrospectively studied. The use of brachytherapy varied among the treating physicians during the study period. A Kaplan-Meier survival analysis was used to estimate disease-free survival and differences between treatment groups were evaluated with the Mantel-Cox statistic. Recurrent disease occurred in 7 patients (5.3%). Vaginal recurrences accounted for 6 of the 7 sites of recurrences. Recurrences occurred in 1.3% of grade 1 vs. 8.7% of grade 2 tumors (P = 0.04). Among 69 grade 2 tumors, recurrences occurred in 7.5% of those treated with brachytherapy vs. 10.3% of those not treated (P = 0.68). Brachytherapy did not affect the disease-free or overall survival. No serious complications directly related to therapy occurred. Vaginal recurrences occur even in early endometrial carcinoma. This study demonstrates no apparent benefit to brachytherapy. A larger study would be required to see a recurrence or survival difference.

show abstract

Analysis of Complications in Patients Receiving Adjuvant Irradiation for Endometrial Carcinoma

Cited by 10 publications

References 0 publications

Endometrial Carcinoma—Relative Effectiveness of Adjuvant Irradiation vs Therapy Reserved for Relapse

Endometrial Carcinoma—Relative Effectiveness of Adjuvant Irradiation vs Therapy Reserved for Relapse

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy

Brachytherapy for early endometrial carcinoma: a comparative study with long-term follow-up

Contact Info

Product

Resources

About